PCM
LXRX icon

Prelude Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Prelude Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.8K Buy
+17,173
New +$25K ﹤0.01% 1154
2019
Q3 		– Sell
-1,083
Closed -$7K – 1905
2019
Q2 		$7K Buy
+1,083
New +$6.48K ﹤0.01% 1462
2018
Q3 		– Sell
-1,200
Closed -$14K – 1907
2018
Q2 		$14K Buy
+1,200
New +$12.3K ﹤0.01% 1426

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Prelude Capital Management's LXRX Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Lexicon Pharmaceuticals (LXRX) in Q1 2026: 17,173 shares worth $26.8K. The stake represents ﹤0.01% of the portfolio and ranks #1154 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in LXRX as recently as Q2 2019.

Prelude Capital Management first reported a position in LXRX in Q2 2018 and has held it in 3 quarters since. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Prelude Capital Management held 17,173 shares of Lexicon Pharmaceuticals worth $26.8K as of Q1 2026.
  • Lexicon Pharmaceuticals was a new Prelude Capital Management position in Q1 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1154 holding.
  • Prelude Capital Management first reported a position in Lexicon Pharmaceuticals in Q2 2018 and has held it in 3 quarters since.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.